Aetna · Bezlotoxumab · US health-plan appeal rights

Bezlotoxumab denied due to quantity / dose limits by Aetna?

Q: How long do I have to appeal a Aetna Bezlotoxumab denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Adult ≥18 yr receiving standard-of-care antibacterial drug treatment (fidaxomicin or vancomycin) for active CDI. At least ONE high-risk feature: age ≥65, immunocompromised, severe CDI episode, OR ≥1 CDI recurrence within prior 6 mo. Single 10 mg/kg IV infusion concurrent with antibiotic course. Not for treatment of active CDI (adjunct only).

Source policy: Aetna CPB on Bezlotoxumab (Zinplava) for CDI Recurrence Prevention

What works in the appeal

Per FDA label (approved Oct 21, 2016) and MODIFY I + MODIFY II (Wilcox NEJM 2017;376(4):305-317), bezlotoxumab is ADD-ON to antibiotic for prevention of recurrence in HIGH-RISK patients — NOT reserved for multiple recurrences. Risk criteria are: age ≥65, immunocompromised, severe CDI, OR ≥1 recurrence within prior 6 mo (ANY ONE qualifies). MODIFY I (n=1452) + MODIFY II (n=1203) showed recurrence 17.4%/15.7% vs 26.7%/25.7% placebo — absolute reduction 9-10%, up to 16-26% in pre-specified high-risk subgroups. Age ≥65 is ONE risk factor, not the only — patients <65 with immunocompromise or prior recurrence qualify equally.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna Bezlotoxumab

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.